RxDoctor Payments Data

Ferdinand Rivera Ortiz, MD

Nephrology · San Juan, PRNPI 1174554356

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 49 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$521
  • AstraZeneca$200
  • Genentech USA, Inc.$107
  • Sobi, Inc$87
  • Caris MPI, Inc.$67
  • PBG Puerto Rico LLC$44
  • plus $96 from 4 others

What the payments were for

  • Food & beverage$1,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson24$521
AstraZeneca6$200
Genentech USA, Inc.5$107
Sobi, Inc4$87
Caris MPI, Inc.3$67
PBG Puerto Rico LLC2$44
Calliditas Therapeutics US Inc.2$43
Merck1$20
AbbVie1$18
Amgen1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 30th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,260
Medicare patients
24
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Polystyrene Sulfonate100$10,773
FarxigaDapagliflozin Propanediol17$10,019
XareltoRivaroxaban14$8,037
SynthroidLevothyroxine Sodium29$2,061
Metolazone15$720
Furosemide125$712
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$310
Calcitriol38$206
Ciprofloxacin Hcl38$201
Doxazosin Mesylate15$191
Nifedipine ErNifedipine12$168
Tamsulosin Hcl17$137
Losartan Potassium18$124
Gabapentin18$112
Amlodipine Besylate31$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$200$10,01917 claims
Johnson & JohnsonXarelto$521$8,03714 claims
AbbVieSynthroid$18$2,06129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →